Drug intelligence / Profile preview

indometacin

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Rectal
01

Overview

Indometacin is a potent non-steroidal anti-inflammatory drug (NSAID) belonging to the indole acetic acid derivative class. It functions as a non-selective inhibitor of the cyclooxygenase enzymes COX-1 and COX-2, which are responsible for the synthesis of prostaglandins from arachidonic acid. By reducing prostaglandin levels, indometacin effectively mitigates pain, fever, and inflammation. The specific product **Tuodu** (also marketed under the **Qingying** trademark) is a rectal suppository formulation manufactured by **Guangdong Xinxing Fenghua Pharmaceutical**. It is widely utilized in clinical practice for the management of inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis, as well as for the acute treatment of gouty arthritis and as an antipyretic for high fever.

Brand names
TuoduQingying妥度清营
Other names
Xinxing Tuodu Qingying ShuanIndometacin Suppositories吲哚美辛栓消炎痛栓
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on indometacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on indometacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call